ikema: sarclisa + CARFILZOMIB
AND DEXAMETHASONE (Kd)

ikema Patient Profiles

Treating with sarclisa + Kd as early as
first relapse
1

Current patient information

68 years of age

Cytogenetic risk
High: t(4;14)
Presence of gain(1q21)
ECOG PS 1
Older age

Diagnosis

Diagnosed 19 months ago after persistent worsening bone pain prompted MRI that identified humeral lesion

1st line

VRd induction → ASCT → bortezomib and lenalidomide maintenance (VGPR for 13 months posttransplant)

1st relapse

Rapid increase in M-spike and abrupt onset of bone pain with PET scan showing FDG-avid disease in the axial and appendicular skeleton

2nd-line treatment considerations for Alice

  • Rapid, aggressive disease progression
  • High cytogenetic risk
  • Presence of gain(1q21)
  • Double refractory to lenalidomide and bortezomib
  • Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a novel PI

This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.

consider sarclisa + Kd AS EARLY AS FIRST RELAPSE1

ASCT=autologous stem cell transplant; ECOG PS=Eastern Cooperative Oncology Group performance status; FDG=fluorodeoxyglucose; mAb=monoclonal antibody; MRI=magnetic resonance imaging; PET=positron emission tomography; PI=proteasome inhibitor; RRMM=relapsed or refractory multiple myeloma; VGPR=very good partial response; VRd=bortezomib, lenalidomide, dexamethasone.

Review the broad and diverse patient population studied in the phase 3 IKEMA trial1

Get in touch with your local sarclisa representative

IKEMA Trial Summary Brochure

An informative brochure that includes the IKEMA trial results for SARCLISA + Kd vs Kd alone

Download the resource.

Current patient information

55 years of age

Cytogenetic risk
Standard
ECOG PS 0
Renal function (eGFR)
44 mL/min/1.73 m2

Diagnosis

Diagnosed ~3 years ago after acute onset of renal insufficiency and hypercalcemia

1st line

VRd induction → ASCT → lenalidomide maintenance (CR for 27 months posttransplant;
recovery of renal function)

1st relapse

Relapsed with hypercalcemia, anemia, and recurring renal insufficiency

2nd-line treatment considerations for Charles

  • High symptom burden at early relapse on lenalidomide maintenance
  • Impaired renal function
  • Refractory to lenalidomide
  • Candidate for a triplet regimen that includes a multimodal anti-CD38 mAb and a novel PI

This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.

consider sarclisa + Kd AS EARLY AS FIRST RELAPSE1

ASCT=autologous stem cell transplant; CR=complete response; ECOG PS=Eastern Cooperative Oncology Group performance status; eGFR=estimated glomerular filtration rate; mAb=monoclonal antibody; PI=proteasome inhibitor; RRMM=relapsed or refractory multiple myeloma; VRd=bortezomib, lenalidomide, dexamethasone.

Review the broad and diverse patient population studied in the phase 3 IKEMA trial1

Get in touch with your local sarclisa representative

IKEMA Trial Summary Brochure

An informative brochure that includes the IKEMA trial results for SARCLISA + Kd vs Kd alone

Download the resource.
Back to topTop